CETP and coronary artery disorder: In the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial, the CETP inhibitor Torcetrapib increased HDL-C levels as expected, but this increase was not paralleled by decreased CHD and the trial was stopped due to elevated risk of cardiac and death events (35).